The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cells.

Chiara NaroMonica De MussoFrancesca Delle MonacheValentina PanzeriPierre de la GrangeClaudio Sette

Published in: Journal of experimental & clinical cancer research : CR (2021)

Our study uncovers an extensive splicing program modulated by NEK2 involving splice variants that confer an invasive phenotype to TNBCs and that might represent, together with NEK2 itself, valuable therapeutic targets for this disease.

Keyphrases

breast cancer cells
quality improvement
stem cells
bone marrow
copy number
transcription factor
anti inflammatory